This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VLON vs. XCUR, CRVO, GNLX, SLN, THTX, AVTE, ADAG, BMEA, ANL, and MGNXShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Exicure (XCUR), CervoMed (CRVO), Genelux (GNLX), Silence Therapeutics (SLN), Theratechnologies (THTX), Aerovate Therapeutics (AVTE), Adagene (ADAG), Biomea Fusion (BMEA), Adlai Nortye (ANL), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical preparations" industry. Vallon Pharmaceuticals vs. Exicure CervoMed Genelux Silence Therapeutics Theratechnologies Aerovate Therapeutics Adagene Biomea Fusion Adlai Nortye MacroGenics Exicure (NASDAQ:XCUR) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation. Does the MarketBeat Community prefer XCUR or VLON? Exicure received 8 more outperform votes than Vallon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Vallon Pharmaceuticals an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformExicureOutperform Votes947.37% Underperform Votes1052.63% Vallon PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Do institutionals and insiders believe in XCUR or VLON? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 8.7% of Vallon Pharmaceuticals shares are owned by institutional investors. 3.9% of Exicure shares are owned by insiders. Comparatively, 37.3% of Vallon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, XCUR or VLON? Exicure has a beta of 3.74, meaning that its share price is 274% more volatile than the S&P 500. Comparatively, Vallon Pharmaceuticals has a beta of -1.14, meaning that its share price is 214% less volatile than the S&P 500. Does the media favor XCUR or VLON? In the previous week, Exicure had 4 more articles in the media than Vallon Pharmaceuticals. MarketBeat recorded 4 mentions for Exicure and 0 mentions for Vallon Pharmaceuticals. Exicure's average media sentiment score of 0.34 beat Vallon Pharmaceuticals' score of 0.00 indicating that Exicure is being referred to more favorably in the media. Company Overall Sentiment Exicure Neutral Vallon Pharmaceuticals Neutral Is XCUR or VLON more profitable? Exicure's return on equity of -190.90% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -190.90% -36.75% Vallon Pharmaceuticals N/A -230.48%-124.89% Which has higher valuation and earnings, XCUR or VLON? Vallon Pharmaceuticals has lower revenue, but higher earnings than Exicure. Vallon Pharmaceuticals is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K106.65-$16.91M-$4.81-1.75Vallon Pharmaceuticals$100K203.58-$7.02M-$0.78-1.94 SummaryExicure beats Vallon Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.36M$6.44B$5.30B$7.34BDividend YieldN/A3.21%5.45%4.30%P/E Ratio-1.946.8921.8617.80Price / Sales203.58230.51380.5297.73Price / CashN/A65.6738.2634.64Price / Book8.395.936.453.98Net Income-$7.02M$142.99M$3.22B$247.81M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$1.51-1.3%N/A+196.1%$20.36M$100,000.00-1.943XCURExicure1.7775 of 5 stars$11.95-6.6%N/A+1,358.2%$75.49M$500,000.00-5.7750Short Interest ↓Gap UpCRVOCervoMed3.449 of 5 stars$8.65-11.4%$27.50+217.9%-61.2%$75.28M$7.14M-4.264Short Interest ↓Gap UpGNLXGenelux0.8086 of 5 stars$2.15-0.5%$18.25+748.8%-31.9%$74.40M$8,000.00-2.2610Gap UpSLNSilence Therapeutics2.0055 of 5 stars$2.46+3.3%$40.67+1,553.8%-85.7%$73.48M$43.26M-1.56100News CoverageGap UpTHTXTheratechnologiesN/A$1.59-3.0%N/A+92.4%$73.11M$85.87M-15.90140Analyst RevisionNews CoverageAVTEAerovate Therapeutics0.8135 of 5 stars$2.52flat$2.25-10.7%-87.3%$72.90MN/A-0.8420Positive NewsADAGAdagene2.5177 of 5 stars$1.51-2.3%$8.00+431.6%-42.0%$70.90M$103,204.000.00260Short Interest ↑Positive NewsBMEABiomea Fusion1.9694 of 5 stars$1.88-6.7%$23.91+1,175.2%-84.9%$70.45MN/A-0.4750ANLAdlai Nortye1.5936 of 5 stars$1.87-0.3%$9.00+382.6%-83.9%$68.82M$5M0.00127Short Interest ↑News CoverageMGNXMacroGenics3.7206 of 5 stars$1.07-3.2%$7.38+592.5%-92.2%$67.82M$148.34M-0.68430News CoveragePositive News Related Companies and Tools Related Companies XCUR Alternatives CRVO Alternatives GNLX Alternatives SLN Alternatives THTX Alternatives AVTE Alternatives ADAG Alternatives BMEA Alternatives ANL Alternatives MGNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VLON) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
